Fortunately, GLP-1 medications like semaglutide are changing the game
Gisondi, P., Cotena, C., Tessari, G
PMID: 34235823
GLP-1 and Amylin Dual Therapy: A Paradigm Shift in Obesity Management
Our findings reveal that TIR did not ameliorate the cognitive dysfunction and oxidative stress caused by DXN, indicating its lack of efficacy in protecting against oxidative stress-induced neurotoxicity in chemobrain
Study participants We identified all adult (aged 20 years) patients with NAFLD and type 2 diabetes who had newly started treatment with non-insulin glucose-lowering drugs (metformin, GLP-1RAs, SGLT2 inhibitors, sulfonylureas, meglitinides, thiazolidinediones, acarbose or dipeptidyl peptidase-4 inhibitors) between 1 January 2013 and 31 December 2021